Critical Contrast: Aptevo Therapeutics (APVO) versus Its Peers
Aptevo Therapeutics (NASDAQ: APVO) is one of 295 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare Aptevo Therapeutics to similar businesses based on the strength of its earnings, risk, analyst recommendations, dividends, profitability, institutional ownership and valuation.
This table compares Aptevo Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aptevo Therapeutics Competitors||-5,519.96%||-454.20%||-42.50%|
Institutional and Insider Ownership
39.2% of Aptevo Therapeutics shares are held by institutional investors. Comparatively, 50.5% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 16.4% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Aptevo Therapeutics and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Aptevo Therapeutics||$36.35 million||-$49.94 million||-0.46|
|Aptevo Therapeutics Competitors||$260.16 million||$66.28 million||-6.62|
Aptevo Therapeutics’ rivals have higher revenue and earnings than Aptevo Therapeutics. Aptevo Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of current ratings for Aptevo Therapeutics and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aptevo Therapeutics Competitors||761||3027||11171||227||2.72|
Aptevo Therapeutics currently has a consensus target price of $6.00, suggesting a potential upside of 146.91%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 36.49%. Given Aptevo Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Aptevo Therapeutics is more favorable than its rivals.
Risk & Volatility
Aptevo Therapeutics has a beta of 3.4, suggesting that its stock price is 240% more volatile than the S&P 500. Comparatively, Aptevo Therapeutics’ rivals have a beta of 6.66, suggesting that their average stock price is 566% more volatile than the S&P 500.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc. is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform. The Company has approximately four products in the areas of hematology and infectious diseases, as well as various investigational-stage product candidates in immuno-oncology. The Company’s investigational-stage product candidates include MOR209/ES414, ES210, ES425, Otlertuzumab and 5E3. Its technology can produce monospecific and multispecific immunotherapeutic proteins that bind to various targets. The Company’s marketed products are WinRho SDF (Rho(D) Immune Globulin Intravenous (Human)), HepaGam B (Hepatitis B Immune Globulin Intravenous (Human)), VARIZIG (Varicella Zoster Immune Globulin (Human)), and IXINITY (coagulation factor IX (recombinant)).
Receive News & Ratings for Aptevo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.